CROI 2010 www.hivandmore.de Design: Quad- und GS-9350 Phase-2-Studien Comparison EVG/GS-9350/TDF/FTC + placebo n = 48 Eligible Subjects 2:1 Treatment-naïve HIV RNA ≥5,000 copies/mL CD4 cells >50 cells/mm3 No Resistance to NRTIs NNRTIs PIs HBV- | slideum.com

CROI 2010 www.hivandmore.de Design: Quad- und GS-9350 Phase-2-Studien Comparison EVG/GS-9350/TDF/FTC + placebo n = 48 Eligible Subjects 2:1 Treatment-naïve HIV RNA ≥5,000 copies/mL CD4 cells >50 cells/mm3 No Resistance to NRTIs NNRTIs PIs HBV-

Download Report

Transcript CROI 2010 www.hivandmore.de Design: Quad- und GS-9350 Phase-2-Studien Comparison EVG/GS-9350/TDF/FTC + placebo n = 48 Eligible Subjects 2:1 Treatment-naïve HIV RNA ≥5,000 copies/mL CD4 cells >50 cells/mm3 No Resistance to NRTIs NNRTIs PIs HBV-